Effects of pentanoate, 4-pentenoate, 3-hydroxybutyrate and insulin on the tissue-levels of long-chain acyl CoA and acylcarnitine in the oxygenated and hypoxic rat atria.
Under hypoxic conditions the atrial contents of long-chain acyl CoA (LCCoA) and long-chain acylcarnitine display a close correlation with the noxious effects of fasting on the atrial functions as well as with the amelioration effected by inhibitors of carnitine palmitoyltransferase I. These findings suggested that fatty acid oxidation was detrimental for the hypoxic atria. However, since changes of the LCCoA and LCCa levels which may occur together with the hypoxic disturbances attained under some other metabolic interventions had not been assessed yet, present investigation aimed to provide information about this issue. At the end of the prehypoxic equilibration period, all the treatments tested evoked a fall of the free-CoA levels whereas free-carnitine, LCCoA and LCCa remained unchanged. In the hypoxic atria, 4-pentenoate, an inhibitor of fatty acid beta-oxidation that also can be oxidized, did not change LCCoA and LCCa levels whereas the readily oxidizable pentanoate evoked a drop of LCCoA. These effects may be due to the trapping of CoA as the short-chain acyl esters of both substances. Since 4-pentenoate and pentanoate were noxious on the hypoxic atria even though they did not increase LCCoA and LCCa contents, it may be inferred that short-chain acyl esters might be deleterious during oxygen shortage. The exposure to 3-hydroxybutyrate, an oxidizable substrate whose availability increases during fasting, did not alter the LCCoA and LCCa contents, agreeing with the weak detrimental effects that it exerts on the hypoxic atria. On the other hand, insulin elicited a rise in the LCCoA and a fall in the LCCa contents. Inasmuch insulin had been shown to improve the performance of the hypoxic atria, these findings suggest that LCCoA might not be involved in the noxious effects of fatty acid oxidation whereas LCCa would be the major toxic catabolite.
Varela
A
A
Cátedra de Fisiología Facultad de Farmacia y Bioquímica and PROSIVAD-CONICET Buenos Aires, Argentina.
Dalamon
V
V
Testoni
G
G
Carregal
M
M
Cerruti
S
S
Savino
E A
EA
D020155:3-Hydroxybutyric Acid / Q000494:pharmacology*; D000214:Acyl Coenzyme A / Q000378:metabolism*; D000332:Aerobiosis; D000818:Animals; D002331:Carnitine / Q000031:analogs & derivatives* / Q000378:metabolism; D015687:Cell Hypoxia; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D005260:Female; D006325:Heart Atria / Q000187:drug effects* / Q000378:metabolism; D007328:Insulin / Q000494:pharmacology*; D008297:Male; D018384:Oxidative Stress; D010100:Oxygen / Q000494:pharmacology*; D010421:Pentanoic Acids / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D000214:Acyl Coenzyme A; D005229:Fatty Acids, Monounsaturated; D007328:Insulin; D010421:Pentanoic Acids; C116917:acylcarnitine; C009785:4-pentenoic acid; C038780:n-pentanoic acid; D002331:Carnitine; D010100:Oxygen; D020155:3-Hydroxybutyric Acid